Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tertiary structure

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6 result(s) found for: Tertiary structure. Displaying page 1 of 1.
    EudraCT Number: 2004-002910-12 Sponsor Protocol Number: 0017 Start Date*: 2005-06-17
    Sponsor Name:Theravance Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Complicated Gram-Positive Skin and Skin Structure Infections with a focus on Pa...
    Medical condition: Complicated Gram-Positive Skin and Skin Structure Infections With a Focus on Patients With Infections Due to Methicillin-Resistant Staphylococcus aureus.
    Disease: Version SOC Term Classification Code Term Level
    7.0 10040872 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002914-12 Sponsor Protocol Number: 0018 Start Date*: 2005-04-13
    Sponsor Name:Theravance Inc.
    Full Title: A phase 3, Randomized, Double-Blind, Multinational Trial of Intravenous Televancin Versus Vancomycin for Treatment of Complicated Gram-positive Skin and Skin Structure Infections with a focus on Pa...
    Medical condition: Complicated Gram-Positive Skin and Skin Structure Infections With a Focus on Patients With Infections Due to Methicillin-Resistant Staphylococcus aureus.
    Disease: Version SOC Term Classification Code Term Level
    7.0 10040872 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001117-13 Sponsor Protocol Number: C3BS-C-11-01 Start Date*: 2012-11-14
    Sponsor Name:Celyad SA
    Full Title: Efficacy and Safety of Bone Marrow-Derived Mesenchymal Cardiopoietic Cells (C3BS-CQR-1) for the Treatment of Chronic Advanced Ischemic Heart Failure
    Medical condition: Chronic advanced symptomatic heart failure secondary to ischemic cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004849 10010684 Congestive heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) HU (Completed) PL (Completed) SE (Completed) ES (Completed) IE (Completed) BG (Completed) LT (Completed) EE (Prematurely Ended) HR (Completed)
    Trial results: View results
    EudraCT Number: 2019-003303-35 Sponsor Protocol Number: IB2019-04 Start Date*: 2021-04-08
    Sponsor Name:Institut Bergonié
    Full Title: Combining epigenetic and immune therapy to beat cancer
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033606 Pancreatic cancer non-resectable LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039494 Sarcoma NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001756-35 Sponsor Protocol Number: 16/0163 Start Date*: 2019-06-21
    Sponsor Name:University of California, San Francisco
    Full Title: A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Clemastine Fumarate as a Remyelinating Agent in Acute Opti...
    Medical condition: acute optic neuritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10030942 Optic neuritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-000127-14 Sponsor Protocol Number: NCT-2017-0516 Start Date*: Information not available in EudraCT
    Sponsor Name:Heidelberg University Hospital
    Full Title: INFORM2 exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
    Medical condition: This trial investigates a novel combination treatment regimen using immune checkpoint inhibition and epigenetic therapy in children with relapsed/refractory/progressive high-risk solid tumors or CN...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 05:20:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA